Ildong Jumps 15% on Re-merger, Stem Cells Surge[K-bio pulse]
[Kim Jinsoo, Edaily Reporter] On the 13th, the pharmaceutical and biotech industry saw intense investor interest as Ildong Pharmaceutical announced the merger of its subsidiary.
Following this, the proposed amendment to the Advanced Regenerative Medicine Act in the National Assembly, which eases regulations on stem cell therapies, drove up the stock prices of stem cell therapy developers Medipost and Kangstem Biotech.
(AI Generated Image) ◇Ildong Pharmaceutical Surges on Subsidiary Re-merger Issue According to KG Zeroin's MP DOCTOR (formerly Market Point), Ildong Pharmaceutical's stock price skyrocketed on the NextTrade (NXT) market that day.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
